-
The big health industry has ushered in a "golden period" of development, and pharmaceutical companies are accelerating their layout
Time of Update: 2023-01-06
js?cdnversion='+~(-new Date()/36e5)];Great health is a global health concept proposed in response to the development of the times, social needs and changes in the disease spectrum, the industry has a strong development momentum and huge market potential.
-
The mergers and acquisitions of listed companies are hot, and there are 3 pharmaceutical companies in 1 day!
Time of Update: 2023-01-06
On the same day, Tailong Pharmaceutical issued an announcement on the participation of the company's wholly-owned subsidiary in the establishment of pharmaceutical industry funds and related party transactions, and the company's wholly-owned subsidiary Tailong Health intends to invest 10 million yuan to establish a new wholly-owned subsidiary Hangzhou Tailong Jintang Enterprise Management Co.
-
Can I participate in "Beijing Universal Health Insurance" with medical insurance from other places? Here comes the Q&A
Time of Update: 2023-01-06
A: Yes. When enrolling, what does the prompt "Please confirm whether the insured is the following groups", [new citizens, public medical care, and other medical insurance conditions that can participate in Beijing Universal Health Insurance]?
-
The reform of DRG's payment method "traditional Chinese medicine" has achieved new results
Time of Update: 2023-01-06
As of the end of October 2022, a total of 1,829 designated medical institutions in 15 coordinated areas in Guangxi have implemented DRG payment, covering 87.
As of the end of October 2022, a total of 1,829 designated medical institutions in 15 coordinated areas in Guangxi have implemented DRG payment, covering 87.
-
The reform of DRG's payment method "traditional Chinese medicine" has achieved new results
Time of Update: 2023-01-06
As of the end of October 2022, a total of 1,829 designated medical institutions in 15 coordinated areas in Guangxi have implemented DRG payment, covering 87.
As of the end of October 2022, a total of 1,829 designated medical institutions in 15 coordinated areas in Guangxi have implemented DRG payment, covering 87.
-
Hanshi Pharmaceutical successfully signed a contract to build a new base for the international cell technology industry
Time of Update: 2023-01-06
On November 8, 2022, the Quanzhou Industry-University-Research Fund Matchmaking Conference, hosted by the Quanzhou Municipal People's Government and jointly organized by Quanzhou Science and Technolo
-
Latest health insurance revenue and expenditure data: Spending on new crown vaccines has decreased significantly
Time of Update: 2023-01-06
Overall, the national basic medical insurance participation rate remained stable, the total income of the medical insurance fund increased by 5.
Overall, the national basic medical insurance participation rate remained stable, the total income of the medical insurance fund increased by 5.
-
The domestic rare disease market space is large, and multinational pharmaceutical companies have increased their layout with new drugs
Time of Update: 2023-01-06
In addition, Sanofi brought a number of new drugs for rare diseases to the Expo, including the first exhibition of the world's first approved nanobody drug Cablivi, which is the first drug targeted for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).
-
Another pharmaceutical company is expected to reap good results in 2022!
Time of Update: 2023-01-06
The reason for the change in performance is that the sales revenue of the company's stapler products in overseas markets increased, and the revenue of the stapler parts business increased compared with the previous year, so that the company's operating income and net profit increased compared with the previous year 。 According to the company's 2022 third quarter report, the main revenue reached 318 million yuan, a year-on-year increase of 3.
-
Bristol-Myers Squibb Dr. Xuejun Cai: "Cosmic gravitational waves" allow patients to benefit from innovation
Time of Update: 2023-01-06
"He emphasized that paying more attention to the needs of Chinese patients is not only reflected in Bristol-Myers Squibb's high focus on the indications of its products in the areas of diseases with high incidence in China, but also in the establishment of mechanisms to ensure that China occupies a very important position in the global development strategy.
-
The beautiful service experience brought by "smart medical insurance" is "accelerating its flight into people's homes"
Time of Update: 2023-01-06
fell illhospitalWhen the elderly Sun Qiangmin, a retired employee in Haidian District, Beijing: There are more than 600 pages of information, and there are dozens of pages of detailed lists of expenses alone.
-
The mergers and acquisitions of listed companies are hot, and there are 3 pharmaceutical companies in 1 day!
Time of Update: 2023-01-06
On the same day, Tailong Pharmaceutical issued an announcement on the participation of the company's wholly-owned subsidiary in the establishment of pharmaceutical industry funds and related party transactions, and the company's wholly-owned subsidiary Tailong Health intends to invest 10 million yuan to establish a new wholly-owned subsidiary Hangzhou Tailong Jintang Enterprise Management Co.
-
Vigorously expanding overseas business has become the development trend of domestic pharmaceutical enterprises!
Time of Update: 2023-01-06
js?cdnversion='+~(-new Date()/36e5)];In recent years, China's biomedical industry has developed rapidly, and more and more pharmaceutical companies have begun to actively promote domestic innovative drugs overseas.
js?cdnversion='+~(-new Date()/36e5)];In recent years, China's biomedical industry has developed rapidly, and more and more pharmaceutical companies have begun to actively promote domestic innovative drugs overseas.
-
Recently, pharmaceutical companies have been keen to participate in funds and invest in biomedicine and other fields
Time of Update: 2023-01-06
【Pharmaceutical Network Industry News】On November 10, Youningwei announced that the company intends to participate in the Shanghai Leading Relay Private Equity Partnership (Limited Partnership) for 50 million yuan, which will mainly focus on digital economy, advanced manufacturing, medical and health, consumer services and other industries to carry out investment.
-
Recently, pharmaceutical companies have been keen to participate in funds and invest in biomedicine and other fields
Time of Update: 2023-01-06
【Pharmaceutical Network Industry News】On November 10, Youningwei announced that the company intends to participate in the Shanghai Leading Relay Private Equity Partnership (Limited Partnership) for 50 million yuan, which will mainly focus on digital economy, advanced manufacturing, medical and health, consumer services and other industries to carry out investment.
-
Multinational pharmaceutical companies have increased their presence in the Chinese market and deepened local cooperation
Time of Update: 2023-01-06
js?cdnversion='+~(-new Date()/36e5)];In recent years, innovative drugs are driving the rapid expansion of China's pharmaceutical market.
js?cdnversion='+~(-new Date()/36e5)];In recent years, innovative drugs are driving the rapid expansion of China's pharmaceutical market.
js?cdnversion='+~(-new Date()/36e5)];In recent years, innovative drugs are driving the rapid expansion of China's pharmaceutical market.
-
The raw materials of the core product of Special Pharmaceutical's cough suppressant tablets are rising!
Time of Update: 2023-01-06
medicinal The market for most of the raw materials of Teyi Pharmaceutical's core product cough suppressant tablets has risen, resulting in greater cost pressure on the company and a decrease in net profit compared with last year.
-
AI pharmaceutical research and development is hot, and transaction cooperation has gradually become an industry trend
Time of Update: 2023-01-06
On October 11, Illumina announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining the strengths of both companies in artificial intelligence (AI)-based genome interpretation and genomic analysis technologies, as well as industry expertise.
-
AI pharmaceutical research and development is hot, and transaction cooperation has gradually become an industry trend
Time of Update: 2023-01-06
On October 11, Illumina announced a strategic research collaboration with AstraZeneca to accelerate drug target discovery by combining the strengths of both companies in artificial intelligence (AI)-based genome interpretation and genomic analysis technologies, as well as industry expertise.
-
The domestic rare disease market space is large, and multinational pharmaceutical companies have increased their layout with new drugs
Time of Update: 2023-01-06
In addition, Sanofi brought a number of new drugs for rare diseases to the Expo, including the first exhibition of the world's first approved nanobody drug Cablivi, which is the first drug targeted for the treatment of acquired thrombotic thrombocytopenic purpura (aTTP).